Cargando…

Rationale for Prostate-Specific-Membrane-Antigen-Targeted Radionuclide Theranostic Applied to Metastatic Clear Cell Renal Carcinoma

Prostate-specific membrane antigen (PSMA), whose high expression has been demonstrated in metastatic aggressive prostate adenocarcinoma, is also highly expressed in the neovessels of various solid tumors, including clear cell renal cell carcinoma (ccRCC). In the VISION phase III clinical trial, PSMA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giraudet, Anne Laure, Vinceneux, Armelle, Pretet, Valentin, Paquet, Emilie, Lajusticia, Alicia Sanchez, Khayi, Fouzi, Badel, Jean Noël, Boyle, Helen, Flechon, Aude, Kryza, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383345/ https://www.ncbi.nlm.nih.gov/pubmed/37513907 http://dx.doi.org/10.3390/ph16070995

Ejemplares similares

3D absorbed dose distribution estimated by Monte Carlo simulation in radionuclide therapy with a monoclonal antibody targeting synovial sarcoma
por: Sarrut, David, et al.
Publicado: (2017)

Unintentional Intra-arterial Injection of (177)Lu-PSMA-1 in a Patient With a Peritoneal Carcinosis Secondary to a Metastatic Prostate Cancer
por: Kryza, David, et al.
Publicado: (2023)

PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?
por: Giraudet, Anne-Laure, et al.
Publicado: (2021)

Yttrium-90 quantitative phantom study using digital photon counting PET
por: Labour, Joey, et al.
Publicado: (2021)

Performance study of a 360° CZT camera for monitoring (177)Lu-PSMA treatment
por: Vergnaud, Laure, et al.
Publicado: (2023)

Subcellular Targeting of Theranostic Radionuclides
por: Bavelaar, Bas M., et al.
Publicado: (2018)

Theranostics: radionuclide imaging and therapy in neuroendocrine tumours
por: Drake, Brent, et al.
Publicado: (2015)

Terbium Radionuclides for Theranostics Applications: A Focus On MEDICIS-PROMED
por: Formento Cavaiera, R, et al.
Publicado: (2020)

Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer
por: D’Huyvetter, Matthias, et al.
Publicado: (2014)

Cyclotron-based production of the theranostic radionuclides $^{67}$Cu and $^{47}$Sc
por: Pupillo, G, et al.
Publicado: (2019)

Photonuclear production, chemistry, and in vitro evaluation of the theranostic radionuclide (47)Sc
por: Loveless, C. Shaun, et al.
Publicado: (2019)

Theranostic SPECT reconstruction for improved resolution: application to radionuclide therapy dosimetry
por: Marquis, H., et al.
Publicado: (2021)

Diagnostic Performance of Theranostic Radionuclides Used in Transarterial Radioembolization for Liver Cancer
por: Li, Rou, et al.
Publicado: (2021)

Production of scandium radionuclides for theranostic applications: towards standardization of quality requirements
por: Mikolajczak, R., et al.
Publicado: (2021)

Patient-specific dosimetry adapted to variable number of SPECT/CT time-points per cycle for [Formula: see text] Lu-DOTATATE therapy
por: Vergnaud, Laure, et al.
Publicado: (2022)

The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker
por: Holik, Holis Abdul, et al.
Publicado: (2022)

Oligonucleotide-Functionalized Gold Nanoparticles for Synchronous Telomerase Inhibition, Radiosensitization, and Delivery of Theranostic Radionuclides
por: Bavelaar, Bas M., et al.
Publicado: (2021)

Copper radionuclides for theranostic applications: towards standardisation of their nuclear data. A mini-review
por: Hussain, Mazhar, et al.
Publicado: (2023)

The Beginning and Development of the Theranostic Approach in Nuclear Medicine, as Exemplified by the Radionuclide Pair (86)Y and (90)Y
por: Rösch, Frank, et al.
Publicado: (2017)

Epigenetic drugs in somatostatin type 2 receptor radionuclide theranostics and radiation transcriptomics in mouse pheochromocytoma models
por: Ullrich, Martin, et al.
Publicado: (2023)

Theranostic Approach for Metastatic Pigmented Melanoma Using ICF15002, a Multimodal Radiotracer for Both PET Imaging and Targeted Radionuclide Therapy()
por: Rbah-Vidal, Latifa, et al.
Publicado: (2016)

Glypican-3 targeted delivery of (89)Zr and (90)Y as a theranostic radionuclide platform for hepatocellular carcinoma
por: Labadie, Kevin P., et al.
Publicado: (2021)

Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer
por: Dho, So Hee, et al.
Publicado: (2018)

First In Vivo and Phantom Imaging of Cyclotron-Produced (133)La as a Theranostic Radionuclide for (225)Ac and (135)La
por: Nelson, Bryce J.B., et al.
Publicado: (2022)

Cyclotron-Based Production of (67)Cu for Radionuclide Theranostics via the (70)Zn(p,α)(67)Cu Reaction
por: Brühlmann, Santiago Andrés, et al.
Publicado: (2023)

Somatostatin Receptor Avidity in Gastrointestinal Stromal Tumors: Theranostic Implications of Gallium-68 Scan and Eligibility for Peptide Receptor Radionuclide Therapy
por: Loaiza-Bonilla, Arturo, et al.
Publicado: (2017)

A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy
por: Yang, Tianhong, et al.
Publicado: (2023)

Urachal Carcinoma with Choroidal, Lung, Lymph Node, Adrenal, Mammary, and Bone Metastases and Peritoneal Carcinomatosis Showing Partial Response after Chemotherapy Treatment with a Modified Docetaxel, Cisplatin and 5-Fluorouracil Regimen
por: Dekeister, Kathleen, et al.
Publicado: (2016)

THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience
por: Baum, Richard P., et al.
Publicado: (2012)

Expanding the Indication for Novel Theranostic 177Lu-Dotatate Peptide Receptor Radionuclide Therapy: Proof-of-Concept of PRRT in Merkel Cell Cancer
por: Kasi, Pashtoon M., et al.
Publicado: (2019)

Chemotherapy in advanced bladder cancer: current status and future
por: Ismaili, Nabil, et al.
Publicado: (2011)

Evaluation of an antibody-PNA conjugate as a clearing agent for antibody-based PNA-mediated radionuclide pretargeting
por: Myrhammar, Anders, et al.
Publicado: (2020)

Single-centre experience with peptide receptor radionuclide therapy for neuroendocrine tumours (NETs): results using a theranostic molecular imaging-guided approach
por: Gordon, S., et al.
Publicado: (2023)

“A New Reconstructive Method after Pancreaticoduodenectomy: the Triple Roux on a “P” Loop. Rationale and Radionuclide Scanning Evaluatlon.”
por: Pescio, Gianluigi, et al.
Publicado: (1996)

La respuesta está en el colágeno : Una solución a la osteoporosis, la tendinitis, la rotura de ligamientos y otros problemas relacionados con su déficit /
por: Lajusticia Bergasa, Ana María, 1924-
Publicado: (2013)

A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients
por: Giraudet, Anne-Laure, et al.
Publicado: (2018)

International Committee for Radionuclide Metrology Symposium on Radionuclide Metrology and its Applications
por: Collective
Publicado: (1992)

International Committee for Radionuclide Metrology Symposium on Radionuclide Metrology and its Applications
por: Bortel, G, et al.
Publicado: (1994)

EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides
por: Handkiewicz-Junak, Daria, et al.
Publicado: (2018)

Efficient Production of the PET Radionuclide (133)La for Theranostic Purposes in Targeted Alpha Therapy Using the (134)Ba(p,2n)(133)La Reaction
por: Brühlmann, Santiago Andrés, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kovrusjk7pnhv6mv5ec6rbc6c7